Femasys Inc. (FEMY) 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Femasys Inc. is a biomedical innovator focused on women's health, specifically reproductive health. The company operates as a single segment entity developing and commercializing therapeutic and diagnostic products. Key products include FemaSeed (FDA-cleared intratubal insemination for infertility) and FemVue (companion diagnostic). The company's primary product candidate is FemBloc, a non-surgical permanent birth control system currently in a pivotal clinical trial for U.S. FDA approval. In March 2025, the company announced CE mark certification for the FemBloc delivery system in the European Union.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Sales | $1,629,108 | $1,071,970 |
| Cost of Sales | $544,903 | $380,069 |
| Gross Profit | $1,084,205 | $691,901 |
| Operating Expenses | $18,870,010 | $15,200,316 |
| Net Loss | $(18,816,628) | $(14,247,124) |
| Cash and Cash Equivalents (Year End) | $3,451,761 | $21,716,077 |
| Convertible Notes Payable (Net) | $5,406,228 | $4,258,179 |
| Accumulated Deficit | $(127,198,257) | $(108,381,629) |
Liquidity: The company reported a net cash outflow from operating activities of $19.4 million in 2024. As of December 31, 2024, cash balances were $3.45 million. Management estimates current cash, combined with approximately $5.4 million raised subsequent to year-end, will fund operations into the third quarter of 2025.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 52.0% to $1.63 million, driven primarily by the commercialization of the FemaSeed product ($509,650 in sales) and a 6.9% increase in FemVue unit sales.
- Expense Increases: Sales and marketing expenses surged 519.9% to $4.03 million due to the recruitment of a commercial team. Research and development expenses rose 14.0% to $8.22 million, primarily due to increased compensation and clinical trial costs for FemBloc.
- Interest Expense: Interest expense increased 869.6% to $1.60 million, largely due to the amortization of debt discount and issuance costs related to the $6.85 million convertible notes issued in November 2023.
- Cash Position: Cash and cash equivalents decreased by $18.26 million year-over-year, reflecting significant operating losses and capital expenditures.
Guidance, Outlook, and Risks
Outlook: The company expects to continue incurring substantial net losses and negative cash flows as it advances the FemBloc pivotal trial and expands commercialization of FemaSeed. Management anticipates needing substantial additional funding to complete FemBloc development and commercialization.
Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit. The company's ability to meet obligations depends on generating sufficient cash flow or securing future financing.
Key Risks:
- Capital Needs: Inability to raise additional equity or debt financing could force the company to delay or cease operations.
- Regulatory Approval: Commercial success is heavily dependent on FDA approval of FemBloc. The pivotal trial is currently enrolling, with the first 50 patients expected to be completed in Q2 2025.
- Debt Obligations: Convertible notes totaling $6.85 million mature in November 2025. The company is restricted from selling securities below $1.18 per share until May 2025, which may limit refinancing options.
- Market Acceptance: Success depends on healthcare practitioner adoption of new procedures (FemaSeed and FemBloc) and securing reimbursement coverage.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.4 million raised post-year-end to bridge the gap until the third quarter of 2025 and assess the timeline for the next capital raise.
- Convertible Note Terms: Review the conversion price ($1.18) and maturity date (Nov 2025) to understand dilution risks and refinancing pressure.
- FemBloc Trial Progress: Monitor enrollment rates for the pivotal FINALE trial (NCT05977751) and the timeline for the interim analysis (300 women) and final analysis (401 women).
- Commercial Execution: Assess the growth trajectory of FemaSeed sales and the effectiveness of the newly hired sales force in penetrating the infertility market.
- European Regulatory Status: Track the final EMA review status for the FemBloc blended polymer, with potential approval expected mid-2025.